Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice

Antiviral Research

Volumn 104, Issue 1, 2014, Pages 93-101

  Koho, Tiia ^a   Koivunen, Minni R L ^b   Oikarinen, Sami ^a   Kummola, Laura ^a,d   Mäkinen, Selina ^a   Mähönen, Anssi J ^a   Sioofy Khojine, Amirbabak ^a   Marjomäki, Varpu ^c   Kazmertsuk, Artur ^c   Junttila, Ilkka ^a,d   Kulomaa, Markku S ^a   Hyöty, Heikki ^a,d   Hytönen, Vesa P ^a,d   Laitinen, Olli H ^b,e  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b Vactech Ltd   (Finland)

^c UNIVERSITY OF JYVÄSKYLÄ   (Finland)

^d PIRKANMAA HOSPITAL DISTRICT   (Finland)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CVB3; Ion exchange chromatography; VLP

Indexed keywords

CVB3; ION EXCHANGE CHROMATOGRAPHY; VLP;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; BACULOVIRIDAE; CHROMATOGRAPHY, ION EXCHANGE; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; ENTEROVIRUS B, HUMAN; FEMALE; GENE ORDER; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNIZATION; MICE; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84894116625     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.01.013     Document Type: Article

References (47)

1. G. Abraham, and R.J. Colonno Many rhinovirus serotypes share the same cellular receptor J. Virol. 51 1984 340 345
2. J.M. Bergelson, M. Chan, K.R. Solomon, N.F. St John, H. Lin, and R.W. Finberg Decay-accelerating factor (CD55), a glycosylphosphatidylinositol- anchored complement regulatory protein, is a receptor for several echoviruses Proc. Natl. Acad. Sci. USA 91 1994 6245 6248
3. J.M. Bergelson, J.A. Cunningham, G. Droguett, E.A. Kurt-Jones, A. Krithivas, J.S. Hong, M.S. Horwitz, R.L. Crowell, and R.W. Finberg Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5 Science 275 1997 1320 1323
4. Y. Chung, M. Ho, J. Wu, W. Chen, J. Huang, S. Chou, and Y. Hu Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge Vaccine 26 2008 1855 1862
5. M.W. Cunningham, S.M. Antone, J.M. Gulizia, B.M. McManus, V.A. Fischetti, and C.J. Gauntt Cytotoxic and viral neutralizing antibodies crossreact with streptococcal M protein, enteroviruses, and human cardiac myosin Proc. Natl. Acad. Sci. USA 89 1992 1320 1324
6. M. Dan, and J.K. Chantler A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection J. Virol. 79 2005 9285 9295
7. J.J. Dunn, S.S. Bradrick, N.M. Chapman, S.M. Tracy, and J.R. Romero The stem loop II within the 5′ nontranslated region of clinical coxsackievirus B3 genomes determines cardiovirulence phenotype in a murine model J. Infect. Dis. 187 2003 1552 1561
8. R. Feuer, I. Mena, R.R. Pagarigan, S. Harkins, D.E. Hassett, and J.L. Whitton Coxsackievirus B3 and the neonatal CNS: the roles of stem cells, developing neurons, and apoptosis in infection, viral dissemination, and disease Am. J. Pathol. 163 2003 1379 1393
9. T. Fifis, A. Gamvrellis, B. Crimeen-Irwin, G.A. Pietersz, J. Li, P.L. Mottram, I.F. McKenzie, and M. Plebanski Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors J. Immunol. 173 2004 3148 3154
10. J. Fohlman, N.G. Ilback, G. Friman, and B. Morein Vaccination of Balb/c mice against enteroviral mediated myocarditis Vaccine 8 1990 381 384
11. E.K. Godney, H.M. Arizpe, and C.J. Gaunti Characterization of the antibody response in vaccinated mice protected against Coxsackievirus B3-induced myocarditis Viral Immunol. 1 1987 305 314
12. M. Goldman, and P.H. Lambert Immunological safety of vaccines: facts hypothesis and allegations S.H.E. Kaufmann, Novel Vaccination Strategies 2004 Wiley-VCH Weinheim, Germany 595 611
13. E.V. Grgacic, and D.A. Anderson Virus-like particles: passport to immune recognition Methods 40 2006 60 65
14. C.M. Haarmann, P.L. Schwimmbeck, T. Mertens, H.P. Schultheiss, and B.E. Strauer Identification of serotype-specific and nonserotype-specific B-cell epitopes of coxsackie B virus using synthetic peptides Virology 200 1994 381 389
15. A. Henke, E. Wagner, J.L. Whitton, R. Zell, and A. Stelzner Protection of mice against lethal Coxsackievirus B3 infection by using DNA immunization J. Virol. 72 1998 8327 8331
16. S. Huber, J. Polgar, A. Moraska, M. Cunningham, P. Schwimmbeck, and P. Schultheiss T lymphocyte responses in CVB3-induced murine myocarditis Scand. J. Infect. Dis. Suppl. 88 1993 67 78
17. G.T. Jennings, and M.F. Bachmann The coming of age of virus-like particle vaccines Biol. Chem. 389 2008 521 536
18. H.R. Karkkainen, H.P. Lesch, A.I. Maatta, P.I. Toivanen, A.J. Mahonen, M.M. Roschier, K.J. Airenne, O.H. Laitinen, and S. Yla-Herttuala A 96-well format for a high-throughput baculovirus generation, fast titering and recombinant protein production in insect and mammalian cells BMC Res. Notes 2 2009 63 10.1186/1756-0500-2-63
19. C.C. Kemball, S. Harkins, and J.L. Whitton Enumeration and functional evaluation of virus-specific CD4+ and CD8+ T cells in lymphoid and peripheral sites of Coxsackievirus B3 infection J. Virol. 82 2008 4331 4342
20. D.S. Kim, and J.H. Nam Application of attenuated Coxsackievirus B3 as a viral vector system for vaccines and gene therapy Hum. Vaccine 7 2011 410 416
21. J.Y. Kim, E.S. Jeon, B.K. Lim, S.M. Kim, S.K. Chung, J.M. Kim, S.I. Park, I. Jo, and J.H. Nam Immunogenicity of a DNA vaccine for Coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge Vaccine 23 2005 1672 1679
22. W.M. Klump, I. Bergmann, B.C. Muller, D. Ameis, and R. Kandolf Complete nucleotide sequence of infectious Coxsackievirus B3 cDNA: two initial 5′ uridine residues are regained during plus-strand RNA synthesis J. Virol. 64 1990 1573 1583
23. K.U. Knowlton, E.S. Jeon, N. Berkley, R. Wessely, and S. Huber A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of Coxsackievirus B3 J. Virol. 70 1996 7811 7818
24. H.G. Krausslich, M.J. Nicklin, C.K. Lee, and E. Wimmer Polyprotein processing in picornavirus replication Biochimie 70 1988 119 130
25. Z.L. Liang, Q.Y. Mao, Y.P. Wang, F.C. Zhu, J.X. Li, X. Yao, F. Gao, X. Wu, M. Xu, and J.Z. Wang Progress on the research and development of inactivated EV71 whole-virus vaccines Hum. Vaccine Immunother. 9 2013 6
26. Y.L. Lin, C.I. Yu, Y.C. Hu, T.J. Tsai, Y.C. Kuo, W.K. Chi, A.N. Lin, and B.L. Chiang Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles Vaccine 30 2012 1305 1312
27. Q. Liu, K. Yan, Y. Feng, X. Huang, Z. Ku, Y. Cai, F. Liu, J. Shi, and Z. Huang A virus-like particle vaccine for Coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge Vaccine 30 2012 6642 6648
28. R. Maier, P. Krebs, and B. Ludewig Immunopathological basis of virus-induced myocarditis Clin. Dev. Immunol. 11 2004 1 5
29. P.C. McMinn Recent advances in the molecular epidemiology and control of human enterovirus 71 infection Curr. Opin. Virol. 2 2012 199 205
30. J.L. Melnick Enteroviruses: polioviruses, Coxsackieviruses, echoviruses and newer enteroviruses B.N. Fields, D.M. Knipe, P.M. Howley, R.M. Channock, J.L. Melnick, T.P. Monath, B. Roizman, S.E. Straus, Fields Virology third ed. 1996 Lippincott-Raven Publishers Philadelphia, PA 655 712
31. I. Mena, C. Fischer, J.R. Gebhard, C.M. Perry, S. Harkins, and J.L. Whitton Coxsackievirus infection of the pancreas: evaluation of receptor expression, pathogenesis, and immunopathology Virology 271 2000 276 288
32. R. Morenweiser Downstream processing of viral vectors and vaccines Gene Ther. 12 Suppl. 1 2005 S103 S110
33. J.H. Park, D.S. Kim, Y.J. Cho, Y.J. Kim, S.Y. Jeong, S.M. Lee, S.J. Cho, C.W. Yun, I. Jo, and J.H. Nam Attenuation of Coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis Vaccine 27 2009 1974 1983
34. M. Roivainen, M. Knip, H. Hyoty, P. Kulmala, M. Hiltunen, P. Vahasalo, T. Hovi, and H.K. Akerblom Several different enterovirus serotypes can be associated with prediabetic autoimmune episodes and onset of overt IDDM. Childhood diabetes in Finland (DiMe) study group J. Med. Virol. 56 1998 74 78
35. B. Rombaut, and J.P. Jore Immunogenic, non-infectious polio subviral particles synthesized in Saccharomyces cerevisiae J. Gen. Virol. 78 Pt 8 1997 1829 1832
36. P. Roy, and R. Noad Virus-like particles as a vaccine delivery system: myths and facts Hum. Vaccine 4 2008 5 12
37. D.M. See, and J.G. Tilles Efficacy of a polyvalent inactivated-virus vaccine in protecting mice from infection with clinical strains of group B Coxsackieviruses Scand. J. Infect. Dis. 26 1994 739 747
38. H.C. Selinka, A. Wolde, M. Sauter, R. Kandolf, and K. Klingel Virus-receptor interactions of Coxsackie B viruses and their putative influence on cardiotropism Med. Microbiol. Immunol. 193 2004 127 131
39. M.K. Slifka, R. Pagarigan, I. Mena, R. Feuer, and J.L. Whitton Using recombinant Coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection J. Virol. 75 2001 2377 2387
40. J. Sprent Immunological memory Curr. Opin. Immunol. 9 1997 371 379
41. E. Stadnick, M. Dan, A. Sadeghi, and J.K. Chantler Attenuating mutations in Coxsackievirus B3 map to a conformational epitope that comprises the puff region of VP2 and the knob of VP3 J. Virol. 78 2004 13987 14002
42. Z. Tu, N.M. Chapman, G. Hufnagel, S. Tracy, J.R. Romero, W.H. Barry, L. Zhao, K. Currey, and B. Shapiro The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5′ nontranslated region J. Virol. 69 1995 4607 4618
43. A. Voigt, S. Jakel, K. Textoris-Taube, C. Keller, I. Drung, G. Szalay, K. Klingel, P. Henklein, K. Stangl, P.M. Kloetzel, and U. Kuckelkorn Generation of in silico predicted Coxsackievirus B3-derived MHC class I epitopes by proteasomes Amino Acids 39 2010 243 255
44. A.H. Wong, C.S. Lau, P.K. Cheng, A.Y. Ng, and W.W. Lim Coxsackievirus B3-associated aseptic meningitis: an emerging infection in Hong Kong J. Med. Virol. 83 2011 483 489
45. W. Xu, Y. Shen, Z. Jiang, Y. Wang, Y. Chu, and S. Xiong Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection Vaccine 22 2004 3603 3612
46. H. Zhang, P. Morgan-Capner, N. Latif, Y.A. Pandolfino, W. Fan, M.J. Dunn, and L.C. Archard Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain Am. J. Pathol. 150 1997 2197 2207
47. L. Zhang, N.J. Parham, F. Zhang, M. Aasa-Chapman, E.A. Gould, and H. Zhang Vaccination with Coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis Vaccine 30 2012 2301 2308